본문 바로가기
KERD
논문KCI 등재

Experimental Animal Models of Coronavirus Infections: Strengths and Limitations

최영기|Casel Mark Anthony B.|Rollon Rare G.
대한면역학회 (The Korean Association of Immunologists)|2021.04|Immune Network|제21권 제2호|pp. 1-17|DOI 10.4110/in.2021.21.e12

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

COVID-19SARS-CoV-2Emerging infectious diseaseAnimal models

초록

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the emergence of SARS-CoV-2 in the human population in late 2019, it has spread on an unprecedented scale worldwide leading to the first coronavirus pandemic. SARS-CoV-2 infection results in a wide range of clinical manifestations from asymptomatic to fatal cases. Although intensive research has been undertaken to increase understanding of the complex biology of SARS-CoV-2 infection, the detailed mechanisms underpinning the severe pathogenesis and interactions between the virus and the host immune response are not well understood. Thus, the development of appropriate animal models that recapitulate human clinical manifestations and immune responses against SARS-CoV-2 is crucial. Although many animal models are currently available for the study of SARS-CoV-2 infection, each has distinct advantages and disadvantages, and some models show variable results between and within species. Thus, we aim to discuss the different animal models, including mice, hamsters, ferrets, and non-human primates, employed for SARS-CoV-2 infection studies and outline their individual strengths and limitations for use in studies aimed at increasing understanding of coronavirus pathogenesis. Moreover, a significant advantage of these animal models is that they can be tailored, providing unique options specific to the scientific goals of each researcher.

Abstract

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the emergence of SARS-CoV-2 in the human population in late 2019, it has spread on an unprecedented scale worldwide leading to the first coronavirus pandemic. SARS-CoV-2 infection results in a wide range of clinical manifestations from asymptomatic to fatal cases. Although intensive research has been undertaken to increase understanding of the complex biology of SARS-CoV-2 infection, the detailed mechanisms underpinning the severe pathogenesis and interactions between the virus and the host immune response are not well understood. Thus, the development of appropriate animal models that recapitulate human clinical manifestations and immune responses against SARS-CoV-2 is crucial. Although many animal models are currently available for the study of SARS-CoV-2 infection, each has distinct advantages and disadvantages, and some models show variable results between and within species. Thus, we aim to discuss the different animal models, including mice, hamsters, ferrets, and non-human primates, employed for SARS-CoV-2 infection studies and outline their individual strengths and limitations for use in studies aimed at increasing understanding of coronavirus pathogenesis. Moreover, a significant advantage of these animal models is that they can be tailored, providing unique options specific to the scientific goals of each researcher.

참고문헌 (99)

  1. Fehr AR, "Coronaviruses : an overview of their replication and pathogenesis", Methods Mol Biol, 1282, pp.1~23 (2015)
  2. Cui J, "Origin and evolution of pathogenic coronaviruses", Nat Rev Microbiol, 17, pp.181~192 (2019)
  3. "Middle East respiratory syndrome coronavirus (MERS-CoV)"[URL]
  4. "Who coronavirus disease (COVID-19) dashboard"[URL]
  5. Li W, "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus", Nature, 426, pp.450~454 (2003)
  6. Kuba K, "A crucial role of angiotensin converting enzyme 2(ACE2)in SARS coronavirus-induced lung injury", Nat Med, 11, pp.875~879 (2005)
  7. Medina-Enríquez MM, "ACE2 : the molecular doorway to SARS-CoV-2", Cell Biosci, 10, pp.148~ (2020)
  8. Harmer D, "Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme", FEBS Lett, 532, pp.107~110 (2002)
  9. Xu X, "Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission", Sci China Life Sci, 63, pp.457~460 (2020)
  10. Li F, "Structure of SARS coronavirus spike receptor-binding domain complexed with receptor", Science, 309, pp.1864~1868 (2005)
  11. Zou J, "Computational prediction of mutational effects on SARS-CoV-2 binding by relative free energy calculations", J Chem Inf Model, 60, pp.5794~5802 (2020)
  12. Zhou P, "A pneumonia outbreak associated with a new coronavirus of probable bat origin", Nature, 579, pp.270~273 (2020)
  13. Zhang H, "Angiotensin-converting enzyme 2(ACE2)as a SARSCoV-2 receptor : molecular mechanisms and potential therapeutic target", Intensive Care Med, 46, pp.586~590 (2020)
  14. Hamming I, "Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis", J Pathol, 203, pp.631~637 (2004)
  15. Tartey S, "Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells", Int Rev Immunol, 36, pp.57~73 (2017)
  16. Takeuchi O, "Pattern recognition receptors and inflammation", Cell, 140, pp.805~820 (2010)
  17. Krieg AM, "AIMing 2 defend against intracellular pathogens", Nat Immunol, 11, pp.367~369 (2010)
  18. Shah VK, "Overview of immune response during SARSCoV-2 infection : lessons from the past", Front Immunol, 11, pp.1949~ (2020)
  19. de Wit E, "SARS and MERS : recent insights into emerging coronaviruses", Nat Rev Microbiol, 14, pp.523~534 (2016)
  20. Wathelet MG, "Severe acute respiratory syndrome coronavirus evades antiviral signaling : role of nsp1 and rational design of an attenuated strain", J Virol, 81, pp.11620~11633 (2007)
  21. Lei X, "Activation and evasion of type I interferon responses by SARS-CoV-2", Nat Commun, 11, pp.3810~ (2020)
  22. Zhao L, "Distribution of Haemaphysalis longicornis and associated pathogens: analysis of pooled data from a China field survey and global published data", Lancet Planet Health, 4, pp.320~e329 (2020)
  23. Devaraj SG, "Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus", J Biol Chem, 282, pp.32208~32221 (2007)
  24. Frieman M, "Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-κB signaling", J Virol, 83, pp.6689~6705 (2009)
  25. Hsueh PR, "Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus", Clin Microbiol Infect, 10, pp.1062~1066 (2004)
  26. Corman VM, "Viral shedding and antibody response in 37 patients with middle east respiratory syndrome coronavirus infection", Clin Infect Dis, 62, pp.477~483 (2016)
  27. Legros V, "A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity", Cell Mol Immunol, 18, pp.318~327 (2021)
  28. Henss L, "Analysis of humoral immune responses in SARS-CoV-2 infected patients", J Infect Dis, 223, pp.56~61 (2020)
  29. Lau EH, "Neutralizing antibody titres in SARS-CoV-2 infections", Nat Commun, 12, pp.63~ (2021)
  30. Luchsinger LL, "Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients", J Clin Microbiol, 58, pp.e02005~e02020 (2020)
  31. Muecksch F, "Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents", J Infect Dis, 223, pp.389~398 (2021)
  32. Wu F, "Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in shanghai, china", JAMA Intern Med, 180, pp.1356~1362 (2020)
  33. Giamarellos-Bourboulis EJ, "Complex immune dysregulation in COVID-19 patients with severe respiratory failure", Cell Host Microbe, 27, pp.992~1000 (2020)
  34. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
  35. Sit TH, "Infection of dogs with SARS-CoV-2", Nature, 586, pp.776~778 (2020)
  36. "USDA statement on the confirmation of COVID-19 in a tiger in New York"[URL]
  37. Emma C. Hobbs, "Animals and SARS‐CoV‐2: Species susceptibility and viral transmission in experimental and natural conditions, and the potential implications for community transmission", Transboundary and Emerging Diseases, 68(4), pp.1850~1867 (2021), Wiley[DOI]
  38. Oreshkova N, "SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020", Euro Surveill, 25, pp.2001005~ (2020)
  39. Mestas J, "Of mice and not men : differences between mouse and human immunology", J Immunol, 172, pp.2731~2738 (2004)
  40. Wan Y, "Receptor recognition by the novel coronavirus from Wuhan : an analysis based on decade-long structural studies of SARS coronavirus", J Virol, 94, pp.e00127~e00120 (2020)
  41. Yang XH, "Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection", Comp Med, 57, pp.450~459 (2007)
  42. McCray PB Jr, "Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus", J Virol, 81, pp.813~821 (2007)
  43. Tseng CT, "Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor", J Virol, 81, pp.1162~1173 (2007)
  44. Netland J, "Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2", J Virol, 82, pp.7264~7275 (2008)
  45. Yoshikawa N, "Differential virological and immunological outcome of severe acute respiratory syndrome coronavirus infection in susceptible and resistant transgenic mice expressing human angiotensin-converting enzyme 2", J Virol, 83, pp.5451~5465 (2009)
  46. Menachery VD, "SARS-like WIV1-CoV poised for human emergence", Proc Natl Acad Sci U S A, 113, pp.3048~3053 (2016)
  47. Bao L, "The pathogenicity of SARSCoV-2 in hACE2 transgenic mice", Nature, 583, pp.830~833 (2020)
  48. Jiang RD, "Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2", Cell, 182, pp.50.e8~58.e8 (2020)
  49. Helms J, "Neurologic features in severe SARS-CoV-2 infection", N Engl J Med, 382, pp.2268~2270 (2020)
  50. Gu H, "Rapid adaptation of SARS-CoV-2 in BALB", c mice : novel mouse model for vaccine efficacy, 2020.05.02.073411, pp.2020, ~
  51. Dinnon KH 3rd, "A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures", Nature, 586, pp.560~566 (2020)
  52. Yun SM, "Genetic and pathogenic diversity of severe fever with thrombocytopenia syndrome virus(SFTSV)in South Korea", JCI Insight, 5, pp.e129531~ (2020)
  53. Hassan AO, "A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies", Cell, 182, pp.744.e4~753.e4 (2020)
  54. Israelow B, "Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling", J Exp Med, 217, pp.e20201241~ (2020)
  55. Rathnasinghe R, "Comparison of transgenic and adenovirus hACE2 mouse models for SARSCoV-2 infection", Emerg Microbes Infect, 9, pp.2433~2445 (2020)
  56. Takao K, "Genomic responses in mouse models greatly mimic human inflammatory diseases", Proc Natl Acad Sci U S A, 112, pp.1167~1172 (2015)
  57. Shay T, "Conservation and divergence in the transcriptional programs of the human and mouse immune systems", Proc Natl Acad Sci U S A, 110, pp.2946~2951 (2013)
  58. Ernst W, "Humanized mice in infectious diseases", Comp Immunol Microbiol Infect Dis, 49, pp.29~38 (2016)
  59. Brumeanu TD, "A Human-ImmuneSystem mouse model for COVID-19 research (DRAGA mouse: HLA-A2.HLA-DR4.Rag1KO.IL-2Rγc KO.NOD)", bioRxiv. doi: 10.1101, 2021 (2020)
  60. Tu W, "Application of humanized mice in immunological research", Methods Mol Biol, 1371, pp.157~176 (2016)
  61. Miao J, "Syrian hamster as an animal model for the study on infectious diseases", Front Immunol, 10, pp.2329~ (2019)
  62. Chan JF, "Simulation of the clinical and pathological manifestations of coronavirus disease 2019(COVID-19)in a golden syrian hamster model : implications for disease pathogenesis and transmissibility", Clin Infect Dis, 71, pp.2428~2446 (2020)
  63. Imai M, "Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development", Proc Natl Acad Sci U S A, 117, pp.16587~16595 (2020)
  64. Sia SF, "Pathogenesis and transmission of SARS-CoV-2 in golden hamsters", Nature, 583, pp.834~838 (2020)
  65. Boudewijns R, "STAT2 signaling as double-edged sword restricting viral dissemination but driving severe pneumonia in SARS-CoV-2 infected hamsters", bioRxiv. doi:10.1101, 2020 (2020)
  66. Wen W, "Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing", Cell Discov, 6, pp.31~ (2020)
  67. Zhang D, "Frontline science : COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes", J Leukoc Biol, 109, pp.13~22 (2021)
  68. Grupp SA, "Chimeric antigen receptor-modified T cells for acute lymphoid leukemia", N Engl J Med, 368, pp.1509~1518 (2013)
  69. Mehta P, "COVID-19: consider cytokine storm syndromes and immunosuppression", Lancet, 395, pp.1033~1034 (2020)
  70. Vardhana SA, "The many faces of the anti-COVID immune response", J Exp Med, 217, pp.e20200678~ (2020)
  71. Brocato RL, "Disruption of adaptive immunity enhances disease in sars-cov-2-infected syrian hamsters", J Virol, 94, pp.e01683~e01620 (2020)
  72. Osterrieder N, "Age-dependent progression of SARS-CoV-2 infection in syrian hamsters", Viruses, 12, pp.779~ (2020)
  73. Trimpert J, "The roborovski dwarf hamster is a highly susceptible model for a rapid and fatal course of Sars-CoV-2 infection", Cell Reports, 33, pp.108488~ (2020)
  74. Cleary SJ, "Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology", Br J Pharmacol, 177, pp.4851~4865 (2020)
  75. Chu YK, "The SARS-CoV ferret model in an infection-challenge study", Virology, 374, pp.151~163 (2008)
  76. Zhang Q, "H7N9 influenza viruses are transmissible in ferrets by respiratory droplet", Science, 341, pp.410~414 (2013)
  77. Stittelaar KJ, "Ferrets as a novel animal model for studying human respiratory syncytial virus infections in immunocompetent and immunocompromised hosts", Viruses, 8, pp.168~ (2016)
  78. Kim YI, "Infection and rapid transmission of SARS-CoV-2 in ferrets", Cell Host Microbe, 27, pp.704.e2~709.e2 (2020)
  79. Shi J, "Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2", Science, 368, pp.1016~1020 (2020)
  80. Johnson-Delaney CA, "Ferret respiratory system : clinical anatomy, physiology, and disease", Vet Clin North Am Exot Anim Pract, 14, pp.357~367, vii (2011)
  81. Enkirch T, "Ferret models of viral pathogenesis", Virology, 479-480, pp.259~270 (2015)
  82. Kim YI, "Critical role of neutralizing antibody for sars-cov-2 reinfection and transmission", Emerg Microbes Infect, 10, pp.152~160 (2021)
  83. "Pandemic coronavirus causing COVID-19"[URL]
  84. Papalexi E, "Single-cell RNA sequencing to explore immune cell heterogeneity", Nat Rev Immunol, 18, pp.35~45 (2018)
  85. Stubbington MJ, "Single-cell transcriptomics to explore the immune system in health and disease", Science, 358, pp.58~63 (2017)
  86. Zhang JY, "Single-cell landscape of immunological responses in patients with COVID-19", Nat Immunol, 21, pp.1107~1118 (2020)
  87. Lee JS, "Single-cell transcriptome of bronchoalveolar lavage fluid reveals dynamic change of macrophages during SARSCoV-2 infection in ferrets", bioRxiv. doi: 10.1101, 2020 (2020)
  88. Yu P, "Age-related rhesus macaque models of COVID-19", Animal Model Exp Med, 3, pp.93~97 (2020)
  89. Singh DK, "Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets", Nat Microbiol, 6, pp.73~86 (2021)
  90. Lu S, "Comparison of nonhuman primates identified the suitable model for COVID-19", Signal Transduct Target Ther, 5, pp.157~ (2020)
  91. Bao L, "Lack of reinfection in rhesus macaques infected with SARS-CoV-2", bioRxiv, doi: 10.1101, 2020 (2020)
  92. Rockx B, "Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model", Science, 368, pp.1012~1015 (2020)
  93. Woolsey C, "Establishment of an African green monkey model for COVID-19 and protection against re-infection", Nat Immunol, 22, pp.86~98 (2021)
  94. Liu R, "Decreased T cell populations contribute to the increased severity of COVID-19", Clin Chim Acta, 508, pp.110~114 (2020)
  95. Wilk AJ, "A single-cell atlas of the peripheral immune response in patients with severe COVID-19", Nat Med, 26, pp.1070~1076 (2020)
  96. Munster VJ, "Respiratory disease in rhesus macaques inoculated with SARS-CoV-2", Nature, 585, pp.268~272 (2020)
  97. Scientific Committee on Health, Environmental and Emerging Risks (SCHEER), "The need for nonhuman primates in biomedical research, production and testing of products and devices", European Union, ~ (2009)
  98. Maiese A, "Autopsy findings in COVID-19-related deaths : a literature review", Forensic Sci Med Pathol, pp.1~18 (2020)
  99. Mohanty SK, "Severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)and coronavirus disease 19(COVID-19)-anatomic pathology perspective on current knowledge", Diagn Pathol, 15, pp.103~ (2020)

관련 논문AI추천

Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19김두진, 이푸름대한면역학회 · Immune Network2020 · 제20권 제4호Generation of a lethal mouse model expressing human ACE2 and TMPRSS2 for SARS-CoV-2 infection and pathogenesisChoi Ji Hyun, Hwang Insu, Jeong Gi Uk, Kim Hae Soo, Kim Kyun-Do, Kim Kyung-Chang, Kim Seong-Jun, Kwon Young-Chan, Lee Joo-Yeon, Lee Wooseong, Yang Jeong-Sun, Yoon Gun Young생화학분자생물학회 · Experimental and Molecular Medicine2024 · 제56권 Understanding the Host Innate Immune Responses against SARS-CoV-2 Infection and COVID-19 Pathogenesis강연우, 김영민, 문다인, 박수빈, 이건주, 이승우대한면역학회 · Immune Network2021 · 제21권 제1호Distinct Molecular Mechanisms Characterizing Pathogenesis of SARS-CoV-2안대균, Kim Yu-Jin, Lee Su Jin한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2022 · 제32권 제9호Middle East Respiratory Syndrome-Coronavirus Infection into Established hDPP4-Transgenic Mice Accelerates Lung Damage Via Activation of the Pro-Inflammatory Response and Pulmonary Fibrosis김주, 양예린, 장용석, 정용수한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2020 · 제30권 제3호Cynomolgus Macaque Model for COVID-19 Delta Variant박재학, 오한슬, An You Jung, Baek Seung Ho, Hong Jung Joo, Hwang Eun-Ha, Jung Hoyin, Kim Green, Koo Bon-Sang대한면역학회 · Immune Network2022 · 제22권 제6호

이 간행물의 다른 논문 (5건)

Nucleocapsid and Spike Proteins of SARS-CoV-2 Drive Neutrophil Extracellular Trap Formation김선화, 이유빈, 배재성, 진희경, 홍창원, 윤영진pp. 1-8Intranasal Vaccination with Outer-Membrane Protein of Orientia tsutsugamushi induces Protective Immunity Against Scrub Typhus주영준, 구민정, 최상호, 한승현, 윤철희, 손영민, 황규잠, 주혁, 정항진, 길병철, 박성무, 천인수, 심병식, 정운희pp. 1-17Modulation of Pro-inflammatory and Anti-inflammatory Cytokines in the Fat by an Aloe Gel-based Formula, QDMC, Is Correlated with Altered Gut Microbiota김지연, 이성원, 이희태, 박일호, 김경제, 공현석, 송영천, 안진호pp. 1-10CD11b Deficiency Exacerbates Methicillin-Resistant Staphylococcus aureus-Induced Sepsis by Upregulating Inflammatory Responses of Macrophages김혜인, 박성원, 이근욱, 정대철, 권형주, 심현섭, THAPABIKASHpp. 1-19Increase of Vδ2+ T Cells That Robustly Produce IL-17A in Advanced Abdominal Aortic Aneurysm Tissues김정환, 이승준, 신의철, 노태욱, 고영국, 주현철, 박수형, 서인호pp. 1-10
원문 보기